RT-PCR study of purinergic P2 receptors in hematopoietic cell lines
RT-PCR study of purinergic P2 receptors in hematopoietic cell lines
复制标题
DOI：
10.1134/s0006297906060034
复制
发表时间：
2006-06
期刊：
影响因子：
--
通讯作者：
M. Bernhard;K. Ulrich
中科院分区：
文献类型：
--
作者：
M. Bernhard;K. Ulrich
到目前为止，已有7个P2X和15个P2Y受体被鉴定，部分是基于氨基酸序列的同源性。在信使核糖核酸水平上研究了所有克隆的人嘌呤能P2受体在原单核细胞U937细胞、红系K562细胞、未分化、二甲基亚砜分化的粒细胞和phorbol-12-myristate-13-acetate-differentiated单核细胞HL60中的表达。RT-PCR分析显示，在至少部分分析的细胞系中发现了几个P2X受体的表达，而所有的P2Y受体都被发现了。HL60细胞的粒细胞和单核细胞分化导致受体转录的部分戏剧性上调或下调。从U937细胞到K562细胞，从未分化的粒细胞到单核细胞HL60，P2受体在每种细胞类型中的表达数量均显著增加。经归一化为甘油醛-3-磷酸脱氢酶水平的总信使核糖核酸量显示出绝对转录水平的更明显的变异。不同的P2受体表达数量的增加与每个细胞中P2受体总平均mRNA量的增加有关。这种过度表达的现象提示了嘌呤能信号的自我诱导效应，表明它参与了造血，并可能参与了免疫反应的调节。
Seven P2X and fifteen P2Y receptors have been identified to date, partly on the basis of amino acid sequence homologies. The expression of all cloned human purinergic P2 receptors was investigated on the messenger RNA level in promonocytic U937 cells, erythroblastic K562 cells, and undifferentiated, dimethyl sulfoxide-differentiated granulocytic, and phorbol-12-myristate-13-acetate-differentiated monocytic HL60 cells. RT-PCR assays showed expression of several P2X receptors, whereas all P2Y receptors were found in at least some of the analyzed cells lines. Granulocytic and monocytic differentiation of HL60 cells lead to a partly dramatic up-or downregulation of receptor transcripts. The number of different P2 receptors expressed in each cell type showed a significant rise from U937 cells via K562 cells, undifferentiated and granulocytic, to monocytic HL60 cells. The total mRNA amounts being normalized to the glyceraldehyde-3-phosphate dehydrogenase levels demonstrated an even more distinct variability of absolute transcript levels. An increased number of different P2 receptors expressed were associated with an increased total average P2 receptor mRNA amount in each cell. This phenomenon of overexpression suggests self-inductive effects of purinergic signaling indicating its involvement in hematopoiesis and possibly in immunoreactive mediation.